AKTX

Akari Therapeutics Share Price - AKTX

1.58
0.06 (3.95%)
Upgrade to Real-Time
Afterhours (Closed)
1.58
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Level 1 Starter
Monthly Subscription
for only
$15.87
VAT not included
Company Name Stock Ticker Symbol Market Type
Akari Therapeutics PLC AKTX NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
0.06 3.95% 1.58 20:00:00
Open Price Low Price High Price Close Price Previous Close
1.54 1.52 1.625 1.58 1.52
Bid Price Ask Price Spread News
1.52 1.61 0.09 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
567 136,788  1.58  216,426 113,330 0.87 - 2.79
Last Trade Time Type Quantity Stock Price Currency
19:44:36 20  1.58 USD

Akari Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
 60.79M 38.47M 37.15M  -  - -0.55 -2.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
-  - 0.00% - -

more financials information »

News Akari Therapeutics

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

AKTX Historical

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.000.000.000.0000.000.0%
1 Year0.000.000.000.0000.000.0%
3 Years0.000.000.000.0000.000.0%
5 Years0.000.000.000.0000.000.0%

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. The firm earns majority of its revenues from United Kingdom. It operates mainly in United States and United Kingdom.


Your Recent History
NASDAQ
AKTX
Akari Ther..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.